胰腺癌的化学预防：是否已准备好进入临床？
Chemoprevention of pancreatic cancer: ready for the clinic?
机构信息
Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 426, Houston, TX 77030, USA.
出版信息
Cancer Prev Res (Phila). 2010 Nov;3(11):1375-8. doi: 10.1158/1940-6207.CAPR-10-0216.
Abstract
Advances in our molecular, clinical, and epidemiologic understanding of the risk and development of pancreatic cancer offer hope for preventing this disease, which is largely intractable once developed. This perspective on provocative, genetically engineered mouse model work reported by Mohammed et al. (beginning on page 1417 in this issue of the journal) examines the prospects for pancreatic cancer chemoprevention with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI). Despite having limited value in advanced pancreatic cancer, EGFR TKIs show promise in the setting of early pancreatic carcinogenesis.
摘要
我们对胰腺癌风险和发展的分子、临床和流行病学认识的进展为预防这种疾病提供了希望，因为一旦发展，这种疾病在很大程度上是无法治愈的。Mohammed 等人（本期杂志第 1417 页开始）在具有挑战性的基因工程小鼠模型工作的这一观点，探讨了表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）在胰腺癌化学预防中的前景。尽管在晚期胰腺癌中价值有限，但 EGFR TKI 在早期胰腺癌发生的情况下显示出希望。
相似文献
1
Chemoprevention of pancreatic cancer: ready for the clinic?
Cancer Prev Res (Phila). 2010 Nov;3(11):1375-8. doi: 10.1158/1940-6207.CAPR-10-0216.
2
Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
Clin Cancer Res. 2009 Nov 1;15(21):6630-8. doi: 10.1158/1078-0432.CCR-09-1001. Epub 2009 Oct 20.
3
Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Cancer Lett. 2016 Aug 28;379(1):124-33. doi: 10.1016/j.canlet.2016.06.002. Epub 2016 Jun 2.
4
Chemoprevention of murine lung cancer by gefitinib in combination with prostacyclin synthase overexpression.
Lung Cancer. 2010 Oct;70(1):37-42. doi: 10.1016/j.lungcan.2010.01.004. Epub 2010 Jan 29.
5
6
Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR.
Oncotarget. 2016 Mar 29;7(13):16273-81. doi: 10.18632/oncotarget.7586.
7
BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
PLoS Med. 2007 Oct;4(10):1669-79; discussion 1680. doi: 10.1371/journal.pmed.0040315.
8
Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of -mutant Lung Cancer.
Mol Cancer Ther. 2017 Mar;16(3):506-515. doi: 10.1158/1535-7163.MCT-16-0522. Epub 2017 Jan 30.
9
Pharmacological background of EGFR targeting.
Ann Oncol. 2004 Jul;15(7):1007-12. doi: 10.1093/annonc/mdh257.
10
Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma.
Oncotarget. 2015 Oct 20;6(32):33290-305. doi: 10.18632/oncotarget.5396.
引用本文的文献
1
Curcumin induced human gastric cancer BGC-823 cells apoptosis by ROS-mediated ASK1-MKK4-JNK stress signaling pathway.
Int J Mol Sci. 2014 Sep 5;15(9):15754-65. doi: 10.3390/ijms150915754.
2
Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer.
BMC Cancer. 2013 Apr 17;13:194. doi: 10.1186/1471-2407-13-194.
3
Chemoprevention of pancreatic cancer using solid-lipid nanoparticulate delivery of a novel aspirin, curcumin and sulforaphane drug combination regimen.
Int J Oncol. 2012 Dec;41(6):2260-8. doi: 10.3892/ijo.2012.1636. Epub 2012 Sep 21.
4
Deploying mouse models of pancreatic cancer for chemoprevention studies.
Cancer Prev Res (Phila). 2010 Nov;3(11):1382-7. doi: 10.1158/1940-6207.CAPR-10-0258. Epub 2010 Nov 2.
本文引用的文献
1
The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model.
Cancer Prev Res (Phila). 2010 Nov;3(11):1417-26. doi: 10.1158/1940-6207.CAPR-10-0038.
2
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.
J Clin Oncol. 2010 Aug 1;28(22):3605-10. doi: 10.1200/JCO.2009.25.7550. Epub 2010 Jul 6.
3
Body mass index and risk, age of onset, and survival in patients with pancreatic cancer.
JAMA. 2009 Jun 24;301(24):2553-62. doi: 10.1001/jama.2009.886.
4
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.
Science. 2009 Jun 12;324(5933):1457-61. doi: 10.1126/science.1171362. Epub 2009 May 21.
5
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.
Science. 2008 Sep 26;321(5897):1801-6. doi: 10.1126/science.1164368. Epub 2008 Sep 4.
6
The natural history of hereditary pancreatitis: a national series.
Gut. 2009 Jan;58(1):97-103. doi: 10.1136/gut.2008.149179. Epub 2008 Aug 28.
7
Pancreatic LKB1 deletion leads to acinar polarity defects and cystic neoplasms.
Mol Cell Biol. 2008 Apr;28(7):2414-25. doi: 10.1128/MCB.01621-07. Epub 2008 Jan 28.
8
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
J Clin Oncol. 2007 May 20;25(15):1960-6. doi: 10.1200/JCO.2006.07.9525. Epub 2007 Apr 23.
9
Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas.
Cancer Cell. 2007 Mar;11(3):229-43. doi: 10.1016/j.ccr.2007.01.017.
10
Genetics and biology of pancreatic ductal adenocarcinoma.
Genes Dev. 2006 May 15;20(10):1218-49. doi: 10.1101/gad.1415606.
Zotero 插件